DEA Schedule I Ban Threatens Research into Promising Opioid Treatment
The DEA’s decision to place a drug in Schedule I has drawn concern from researchers studying its potential use as an opioid treatment. Some opioid users have described the drug as a miracle, while researchers say the ban could prevent further studies of its therapeutic value.
The dispute highlights a tension between regulatory restrictions and efforts to evaluate treatments for opioid use. Schedule I classification limits the legal research and clinical development of substances considered to have a high potential for abuse and no accepted medical use. Researchers warned that this restriction could undermine work on a treatment that might otherwise help people who use opioids.